
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid Ltd is advancing its lead product candidate, D-PLEX100, which has demonstrated significant efficacy in reducing surgical site infections (SSIs) and mortality by 54% when combined with standard-of-care in patients with extensive incision lengths. The ongoing SHIELD II trial is expected to yield a favorable interim analysis, with the potential for early halting and subsequent filing for regulatory approval based on strong preliminary data. Financial projections indicate a decreasing net loss per share from $4.83 in 2024 to $2.41 in 2025, reflecting potential improvement in the company's financial position as clinical milestones are achieved.
Bears say
PolyPid Ltd faces a negative outlook primarily due to ongoing financial losses, exemplified by a reported third-quarter net loss of $1.22 per share, which exceeded expectations and was driven by higher-than-anticipated research and development expenditures. Additionally, the company's commercial risks are exacerbated by competition and pricing pressures, along with geopolitical tensions in the Middle East, which may disrupt operations. Lastly, the uncertainties surrounding the Phase 3 SHIELD II trial of D-PLEX100 and potential dilution risks further contribute to concerns regarding the company's financial stability and outlook.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares